Biotech Values

[DewDiligence]

I hear BMY often under the theory they want to acquire active immuno properties to salvage all the $$$ they spent on ipi.

That’s unduly cynical, IMO. BMY wants to maintain a leadership position in immuno-oncology for the simple reason that they think it’s a great field to be in.